Patients with PsA have a higher prevalence of MetS compared with members of the general population and individuals with other inflammatory arthropathies.

Treatment with guselkumab led to improvements in disease activity over 1 year among patients with PsA and showed a high retention rate.

“The true prevalence of nonadherence to DMARDs in RA is unknown, and the factors that are associated with nonadherence have not been clearly defined,” the authors note. “This is further complicated by ...

Pregnancies with psoriatic arthritis are associated with increased odds of preterm births, with disease load before pregnancy ...